Fosfomycin Resistance in Escherichia coli Isolates from South Korea and in vitro Activity of Fosfomycin Alone and in Combination with Other Antibiotics

Antibiotics
Hyeri SeokKwan Soo Ko

Abstract

We investigated fosfomycin susceptibility in Escherichia coli clinical isolates from South Korea, including community-onset, hospital-onset, and long-term care facility (LTCF)-onset isolates. The resistance mechanisms and genotypes of fosfomycin-resistant isolates were also identified. Finally, the in vitro efficacy of combinations of fosfomycin with other antibiotics were examined in susceptible or extended spectrum β-lactamase (ESBL)-producing E. coli isolates. The fosfomycin resistance rate was 6.7% and was significantly higher in LTCF-onset isolates than community-onset and hospital-onset isolates. Twenty-one sequence types (STs) were identified among 19 fosfomycin-resistant E. coli isolates, showing diverse genotypes. fosA3 was found in only two isolates, and diverse genetic variations were identified in three genes associated with fosfomycin resistance, namely, GlpT, UhpT, and MurA. Some fosfomycin-resistant E. coli isolates carried no mutations. In vitro time-kill assays showed that fosfomycin alone did not exhibit an excellent killing activity, compared with ciprofloxacin in susceptible isolates and with ertapenem in ESBL producers. However, combining fosfomycin with cefixime or piperacillin-tazobactam eradicated suscep...Continue Reading

References

May 10, 1974·Annals of the New York Academy of Sciences·F M KahanH Kropp
Jul 13, 2002·The American Journal of Medicine·Betsy Foxman
Aug 26, 2003·Antimicrobial Agents and Chemotherapy·Annika I NilssonDan I Andersson
May 13, 2006·Molecular Microbiology·Thierry WirthMark Achtman
May 1, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Matthew E FalagasPetros I Rafailidis
Jan 15, 2010·International Journal of Antimicrobial Agents·Sho TakahataKazunori Tomono
Jun 25, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James R JohnsonMariana Castanheira
Nov 19, 2011·The Journal of Antimicrobial Chemotherapy·Drosos E KarageorgopoulosMatthew E Falagas
Aug 9, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aylin ColpanUNKNOWN VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators
Sep 17, 2014·International Journal of Antimicrobial Agents·Michael KreskenUNKNOWN Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy
Jun 2, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C G Giske
Jan 27, 2016·Emerging Infectious Diseases·Ana C MendesLuísa Peixe
Mar 1, 2016·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Sangeeta Sastry, Yohei Doi
Jan 1, 2013·Antibiotics·Alfredo Castañeda-GarcíaAlexandro Rodríguez-Rojas
Jan 8, 2017·Cold Spring Harbor Perspectives in Medicine·Lynn L Silver
Oct 1, 2018·International Journal of Antimicrobial Agents·Matthew E FalagasKonstantinos Z Vardakas

❮ Previous
Next ❯

Citations

Nov 17, 2020·Frontiers in Microbiology·Vincent CattoirFrançois Guérin
Jul 11, 2021·The Journal of Antibiotics·Cristiane Dos SantosOctávio Luiz Franco

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.